Articles tagged "Co-stimulation"

2019 American Transplant Congress
Interruption of Notch Signaling via Blockade of Delta-Like Ligands 1 and 4 Prevents Co-Stimulation Blockade Resistant Allograft Rejection
A. Matar, Y. Dong, B. Lovasik, D. Mathews, A. Ghosh, C. Breeden, A. Stephenson, W. Kitchens, A. Adams
Surgery and Transplantation, Emory University, Atlanta, GA
*Purpose: Co-stimulation blockade (CoB) has emerged as a promising immunosuppression strategy with the advent of belatacept, a novel CTLA4-Ig fusion protein that blocks CD28-mediated T…
2019 American Transplant Congress
Efficacy of Belatacept Conversion Protocols
M. Yazdi, J. Kahwaji, S. Meguerditchian, R. Lee
Kaiser Los Angeles Medical Center, Los Angeles, CA
*Purpose: Belatacept (bela) is approved for de novo use in kidney transplantation. Conversion from CNI to bela is utilized for various reasons. Conversion is off-label…
2019 American Transplant Congress
ECDI-Treated Donor Leukocytes in Primate Cardiac Allograft Recipients
Z. Alikhassy Habibabady¹, T. Zhang², W. Sun², X. Cheng², L. Burdorf¹, I. Tatarov², S. Sendil², I. Behroozfard², B. Cerel¹, D. Parsell², R. N. Pierson III¹, X. Luo³, A. M. Azimzadeh¹
¹Surgery, Massachusetts General Hospital and Harvard School of Medicine, Boston, MA, ²Surgery, University of Maryland School of Medicine, Baltimore, MD, ³Duke Transplant Center, Duke University, Durham, NC
*Purpose: Ethyl carbodiimide (ECDI)-fixed donor leukocytes exhibit tolerogenic immunomodulation in murine models of autoimmunity and transplantation, and nonhuman primate islet transplantation. Here in pilot studies…
2019 American Transplant Congress
Anti- CD154 / CD40 Costimulation Blockade is Superior to Tacrolimus in Prolonging Survival in Pig-to-Nonhuman Primate Renal Xenotransplantation
B. P. Lovasik¹, A. J. Matar¹, C. Breeden¹, J. Jenkins², J. Tector³, S. C. Kim¹, A. B. Adams¹
¹Emory Transplant Center, Emory University, Atlanta, GA, ²Yerkes National Primate Center, Emory University, Atlanta, GA, ³University of Alabama at Birmingham, Birmingham, AL
*Purpose: Costimulation blockade strategies targeting the CD40/CD154 pathway are highly effective in preventing xenograft rejection in pig-to-nonhuman primate (NHP) transplantation models. The aim of this…
2019 American Transplant Congress
Implementation of a De Novo Belatacept Protocol
D. Wojciechowski¹, M. Jacobs², K. Safa¹, H. Gilligan¹, H. Eliot¹, W. W. Williams, Jr¹
¹Massachusetts General Hospital, Boston, MA, ²Wake Forest, Winston-Salem, NC
*Purpose: The use of belatacept with basiliximab induction and maintenance MMF/prednisone when compared to cyclosporine is associated with superior long-term patient and graft survival but…
2019 American Transplant Congress
Expansion of Regulatory T and B Cells in Swine Rendered Tolerant of Allogeneic Vascularized Composite Allografts via Mixed Chimerism
G. Saviane¹, A. Lellouch¹, A. Andrews¹, L. Lantieri², M. Randolph¹, G. Benichou¹, C. Cetrulo Jr¹
¹Center for Transplantation Sciences, Division of Plastic Surgery, Boston, MA, USA, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ²European Georges Pompidou Hospital, University of Paris, Department of Plastic Surgery, Paris, France
*Purpose: Prevention of acute rejection of vascularized composite allografts (VCAs) requires ongoing systemic immunosuppression, which subject patients to infectious, metabolic, reno-vascular and neoplastic complications. It…
2019 American Transplant Congress
Early Conversion to Belatacept in High Risk Renal Transplant Recipients
A. Santeusanio, A. Bhansali, R. Shapiro, V. Delaney, S. Florman, G. De Boccardo
Mount Sinai Hospital, New York, NY
*Purpose: This study describes our experience with early conversion to belatacept therapy in a diverse patient population including patients with donor specific antibodies (DSA). The…
2019 American Transplant Congress
Belatacept Monotherapy in Kidney Transplant Recipients with Failed Allografts Reduces Humoral Sensitization in a Single Center Randomized Controlled Trial
I. R. Badell, R. Elbein, R. A. Bray, H. M. Gebel, A. B. Adams, C. P. Larsen
Emory University School of Medicine, Atlanta, GA
*Purpose: Kidney transplant recipients with failed allografts suffer from high rates of humoral sensitization. Immunosuppression (IS) strategies are highly variable in these patients with many…
2019 American Transplant Congress
Clinical Implications of Belatacept Conversion in a High-Risk, Urban Renal Transplant Population
B. Valdepenas, J. Benken, E. Benedetti, Z. Hajjiri, A. Lichvar
University of Illinois at Chicago, Chicago, IL
*Purpose: Conversion to belatacept as maintenance immunosuppression has gained traction to prevent calcineurin inhibitor (CNI) induced toxicities in renal transplant (RTx) recipients. However, limited knowledge…
2019 American Transplant Congress
Four-Year Follow Up of Kidney Transplantation Using Alemtuzumab Induction and Belatacept/Sirolimus Maintenance Therapy
A. Kirk¹, H. Xu¹, A. Ghali², A. Mehta², A. Guasch²
¹Surgery, Duke University, Durham, NC, ²Transplant Center, Emory University, Atlanta, GA
*Purpose: Kidney transplantation remains limited by the chronic toxicities associated with calcineurin inhibitors (CNIs) and steroids. The objective of this clinical trial was to determine…